A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.
A phase II study with a safety lead-in of nivolumab in combination with bevacizumab or in combination with bevacizumab and rucaparib for the treatment of relapsed epithelial ovarian, fallopian tube or peritoneal cancer
- ClinicalTrials.gov Identifier: NCT02873962
- Protocol Number: 16-263
- Principal Investigator: Meghan Shea
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required